The chemical class known as Troponin I-FS inhibitors encompasses a group of small molecules that target and interact with the troponin I-FS protein, a key component of the troponin complex found in striated muscle cells. Troponin I-FS (fast skeletal) is an isoform of troponin I that plays a vital role in regulating muscle contraction by controlling the interaction between actin and myosin filaments. This interaction is essential for muscle contraction, as it enables the sliding of actin and myosin filaments, leading to muscle fiber shortening. Troponin I-FS inhibitors function by modulating this interaction, which ultimately impacts muscle contractility. The mechanism of action of Troponin I-FS inhibitors involves direct interaction with troponin I-FS or its associated partners within the troponin complex. These inhibitors often bind to specific regions of troponin I-FS, altering its conformation or hindering its ability to interact with other proteins, such as troponin C and actin.
By doing so, these inhibitors disrupt the finely tuned regulatory mechanisms that govern muscle contraction. Some Troponin I-FS inhibitors interfere with the troponin I-FS and troponin C interaction, preventing the conformational changes necessary for the troponin complex to initiate the movement of tropomyosin and facilitate the binding of myosin to actin. Furthermore, Troponin I-FS inhibitors may also impact the overall calcium sensitivity of the contractile apparatus, further influencing muscle contractility. As these inhibitors modulate the troponin complex, they affect the availability of binding sites for calcium ions, which are crucial for initiating the process of muscle contraction. The intricate interplay between troponin I-FS, troponin C, tropomyosin, and actin is disrupted by the presence of these inhibitors, resulting in an altered regulation of muscle contraction. Overall, Troponin I-FS inhibitors represent a class of compounds that provide valuable insights into the complex molecular interactions governing muscle physiology, and their study contributes to a deeper understanding of muscle function at the molecular level.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Omecamtiv Mecarbil | 873697-71-3 | sc-507399 | 5 mg | $255.00 | ||
CK-1827452 inhibits troponin I-fs by disrupting the interaction between troponin I and troponin C, thereby preventing proper regulation of muscle contraction. | ||||||
SB 218078 | 135897-06-2 | sc-203692 | 1 mg | $136.00 | 1 | |
SB-218078 disrupts troponin I-fs function by inhibiting the interaction between troponin I and actin, leading to impaired muscle contraction. | ||||||
(±)-Blebbistatin | 674289-55-5 | sc-203532B sc-203532 sc-203532A sc-203532C sc-203532D | 5 mg 10 mg 25 mg 50 mg 100 mg | $183.00 $313.00 $464.00 $942.00 $1723.00 | 7 | |
Blebbistatin inhibits troponin I-fs by disrupting the actin-myosin interaction, preventing muscle contraction. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Latrunculin A disrupts troponin I-fs function by preventing actin polymerization, thereby impairing muscle contraction. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7 inhibits troponin I-fs by modulating myosin light chain kinase activity, leading to altered muscle contractility. | ||||||
SMIFH2 | 340316-62-3 | sc-507273 | 5 mg | $140.00 | ||
SMIFH2 disrupts troponin I-fs by inhibiting formin-mediated actin filament formation, resulting in impaired muscle contraction. | ||||||
W-7 | 61714-27-0 | sc-201501 sc-201501A sc-201501B | 50 mg 100 mg 1 g | $166.00 $306.00 $1675.00 | 18 | |
W-7 interferes with troponin I-fs function by blocking calmodulin activity, which is essential for proper muscle contraction. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
ML-9 inhibits troponin I-fs by suppressing myosin light chain kinase activity, leading to reduced muscle contractility. | ||||||
CK-869 | 388592-44-7 | sc-507274 | 5 mg | $163.00 | ||
CK-869 interferes with troponin I-fs function by modulating the activity of the Rho-associated protein kinase (ROCK) pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits troponin I-fs by targeting Rho-associated protein kinase (ROCK), leading to impaired regulation of muscle contraction. | ||||||